Krystal Biotech, Inc. (KRYS)
Largest Insider Buys in Sector
KRYS Stock Price History Chart
KRYS Stock Performance
About Krystal Biotech, Inc.
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other …
Insider Activity of Krystal Biotech, Inc.
Over the last 12 months, insiders at Krystal Biotech, Inc. have bought $0 and sold $81.42M worth of Krystal Biotech, Inc. stock.
On average, over the past 5 years, insiders at Krystal Biotech, Inc. have bought $0 and sold $40.36M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 50,000 shares for transaction amount of $1M was made by Krishnan Suma (Chief Operating Officer) on 2018‑10‑18.
List of Insider Buy and Sell Transactions, Krystal Biotech, Inc.
| 2024-12-13 | Sale | President, R&D | 50,000 0.1739% | $164.80 | $8.24M | +2.43% | ||
| 2024-12-13 | Sale | President and CEO | 50,000 0.1739% | $164.80 | $8.24M | +2.43% | ||
| 2024-09-12 | Sale | President, R&D | 50,000 0.1759% | $197.77 | $9.89M | -8.01% | ||
| 2024-09-12 | Sale | President and CEO | 50,000 0.1759% | $197.77 | $9.89M | -8.01% | ||
| 2024-06-11 | Sale | President, R&D | 50,000 0.1734% | $175.76 | $8.79M | +3.77% | ||
| 2024-06-11 | Sale | President and CEO | 50,000 0.1734% | $175.76 | $8.79M | +3.77% | ||
| 2024-05-20 | Sale | director | 20,000 0.0699% | $164.13 | $3.28M | +10.70% | ||
| 2024-03-11 | Sale | President, R&D | 50,000 0.1773% | $170.95 | $8.55M | +4.25% | ||
| 2024-03-11 | Sale | President and CEO | 50,000 0.1773% | $170.95 | $8.55M | +4.25% | ||
| 2024-02-28 | Sale | Chief Accounting Officer | 12,200 0.0438% | $165.94 | $2.02M | +8.77% | ||
| 2024-02-28 | Sale | Chief Accounting Officer | 11,997 0.0431% | $165.88 | $1.99M | +8.77% | ||
| 2024-02-28 | Sale | Chief Accounting Officer | 10,600 0.0381% | $166.10 | $1.76M | +8.77% | ||
| 2024-02-26 | Sale | Chief Accounting Officer | 8,087 0.025% | $136.91 | $1.11M | +12.83% | ||
| 2024-01-22 | Sale | Chief Accounting Officer | 2,500 0.0088% | $130.00 | $325,000 | +33.88% | ||
| 2023-12-11 | Sale | President, R&D | 50,000 0.1761% | $105.67 | $5.28M | +62.15% | ||
| 2023-12-11 | Sale | President and CEO | 50,000 0.1761% | $105.67 | $5.28M | +62.15% | ||
| 2023-09-11 | Sale | President, R&D | 50,000 0.1769% | $127.23 | $6.36M | +20.36% | ||
| 2023-09-11 | Sale | President and CEO | 50,000 0.1769% | $127.23 | $6.36M | +20.36% | ||
| 2023-06-09 | Sale | director | 18,935 0.0736% | $128.77 | $2.44M | -4.32% | ||
| 2023-06-09 | Sale | Chief Commercial Officer | 12,500 0.0485% | $128.61 | $1.61M | -4.32% |
Insider Historical Profitability
| Krishnan Krish S | President and CEO | 1475882 5.1316% | $164.83 | 3 | 25 | +37.18% |
| Krishnan Suma | President, R&D | 1475882 5.1316% | $164.83 | 4 | 28 | +56.24% |
| JANNEY DANIEL | director | 107362 0.3733% | $164.83 | 1 | 8 | +1.89% |
| NORBY R DOUGLAS | director | 9000 0.0313% | $164.83 | 1 | 0 | +106.7% |
| Riley Antony A | Chief Financial Officer | 2800 0.0097% | $164.83 | 1 | 0 | +100% |
Institutional Investor Ownership
| Fidelity Investments | $755.12M | 14.86 | 4.24M | +77.87% | +$330.59M | 0.05 | |
| Avoro Capital Advisors Llc | $454.71M | 8.95 | 2.56M | -0.39% | -$1.78M | 5.45 | |
| The Vanguard Group | $432.86M | 8.52 | 2.43M | -0.12% | -$532,900.35 | 0.01 | |
| BlackRock | $321.23M | 6.32 | 1.81M | -0.23% | -$741,612.24 | 0.01 | |
| Redmile Group | $268.36M | 5.28 | 1.51M | -12.98% | -$40.02M | 2.74 |